Inspire Medical Systems, Inc. (NYSE:INSP) CTO John Rondoni Sells 583 Shares

Inspire Medical Systems, Inc. (NYSE:INSP - Get Free Report) CTO John Rondoni sold 583 shares of the company's stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $170.49, for a total value of $99,395.67. Following the sale, the chief technology officer now owns 10,424 shares in the company, valued at approximately $1,777,187.76. This trade represents a 5.30 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

John Rondoni also recently made the following trade(s):

• On Tuesday, January 7th, John Rondoni sold 58 shares of Inspire Medical Systems stock. The shares were sold at an average price of $215.00, for a total value of $12,470.00.

Inspire Medical Systems Price Performance

NYSE INSP traded down $2.42 during midday trading on Friday, hitting $184.73. 680,965 shares of the company traded hands, compared to its average volume of 564,408. The company has a market cap of $5.48 billion, a PE ratio of 172.65 and a beta of 1.32. The company's 50-day simple moving average is $189.11 and its 200-day simple moving average is $191.33. Inspire Medical Systems, Inc. has a 52 week low of $123.00 and a 52 week high of $257.40.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last released its quarterly earnings data on Monday, February 10th. The company reported $1.15 earnings per share for the quarter, beating analysts' consensus estimates of $0.74 by $0.41. Inspire Medical Systems had a return on equity of 5.30% and a net margin of 4.37%. On average, research analysts predict that Inspire Medical Systems, Inc. will post 1.33 earnings per share for the current year.

Institutional Investors Weigh In On Inspire Medical Systems

Institutional investors have recently modified their holdings of the business. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in shares of Inspire Medical Systems during the 3rd quarter valued at about $1,929,000. Thrivent Financial for Lutherans boosted its holdings in Inspire Medical Systems by 39.7% in the 3rd quarter. Thrivent Financial for Lutherans now owns 110,580 shares of the company's stock worth $23,337,000 after buying an additional 31,444 shares during the last quarter. Allspring Global Investments Holdings LLC increased its stake in Inspire Medical Systems by 798.3% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 267,852 shares of the company's stock worth $56,530,000 after buying an additional 238,034 shares in the last quarter. Merit Financial Group LLC purchased a new stake in Inspire Medical Systems during the 4th quarter worth approximately $313,000. Finally, Principal Financial Group Inc. increased its stake in Inspire Medical Systems by 3,812.6% during the 3rd quarter. Principal Financial Group Inc. now owns 141,089 shares of the company's stock worth $29,777,000 after buying an additional 137,483 shares in the last quarter. 94.91% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

INSP has been the topic of a number of analyst reports. Bank of America raised Inspire Medical Systems from a "neutral" rating to a "buy" rating and upped their target price for the company from $220.00 to $255.00 in a research note on Wednesday, November 20th. Wells Fargo & Company cut their target price on Inspire Medical Systems from $198.00 to $195.00 and set an "equal weight" rating on the stock in a research note on Tuesday. Robert W. Baird cut their target price on Inspire Medical Systems from $252.00 to $248.00 and set an "outperform" rating on the stock in a research note on Tuesday. Morgan Stanley cut their target price on Inspire Medical Systems from $230.00 to $220.00 and set an "overweight" rating on the stock in a research note on Tuesday. Finally, Piper Sandler cut their target price on Inspire Medical Systems from $260.00 to $233.00 and set an "overweight" rating on the stock in a research note on Monday, February 10th. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $228.82.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.